InnoCare Announces First Subject Dosed in Clinical Trial of TYK2 JH2 Allosteric Inhibitor ICP-488 in China
BEIJING–(BUSINESS WIRE)–InnoCare Pharma (HKEX: 09969), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the first subject has been dosed in clinical trial of the Company’s TYK2 JH2 allosteric inhibitor ICP-488 in China. ICP-488 is a potent and selective TYK2 (tyrosine kinase 2) allosteric inhibitor being developed for … [Read more…]
